Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples

Barbara Kinga Barták, Alexandra Kalmár, Bálint Péterfia, Árpád V. Patai, O. Galamb, Gábor Valcz, S. Spisák, Barnabás Wichmann, Zsófia Brigitta Nagy, Kinga Tóth, Z. Tulassay, P. Igaz, B. Molnár

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aberrant methylation is one of the most frequent epigenetic alterations that can contribute to tumor formation. Cell-free DNA can originate from tumor tissue; therefore, the evaluation of methylation markers in cell-free DNA can be a promising method for cancer screening. Our aim was to develop a panel of biomarkers with altered methylation along the colorectal adenoma-carcinoma sequence in both colonic tissue and plasma. Methylation of selected CpG sites in healthy colonic (n = 15), adenoma (n = 15), and colorectal cancer (n = 15) tissues was analyzed by pyrosequencing. MethyLight PCR was applied to study the DNA methylation of SFRP1, SFRP2, SDC2, and PRIMA1 gene promoters in 121 plasma and 32 biopsy samples. The effect of altered promoter methylation on protein expression was examined by immunohistochemistry. Significantly higher (P < 0.05) DNA methylation levels were detected in the promoter regions of all 4 markers, both in CRC and adenoma tissues compared with healthy controls. Methylation of SFRP1, SFRP2, SDC2, and PRIMA1 promoter sequences was observed in 85.1%, 72.3%, 89.4%, and 80.9% of plasma samples from patients with CRC and 89.2%, 83.8%, 81.1% and 70.3% from adenoma patients, respectively. When applied as a panel, CRC patients could be distinguished from controls with 91.5% sensitivity and 97.3% specificity [area under the curve (AUC) = 0.978], while adenoma samples could be differentiated with 89.2% sensitivity and 86.5% specificity (AUC = 0.937). Immunohistochemical analysis indicated decreasing protein levels of all 4 markers along the colorectal adenoma-carcinoma sequence. Our findings suggest that this methylation biomarker panel allows non-invasive detection of colorectal adenoma and cancer from plasma samples.

Original languageEnglish
Pages (from-to)751-763
Number of pages13
JournalEpigenetics
Volume12
Issue number9
DOIs
Publication statusPublished - Sep 2 2017

Fingerprint

Adenoma
Methylation
Colorectal Neoplasms
DNA Methylation
Area Under Curve
Biomarkers
Sensitivity and Specificity
DNA
Early Detection of Cancer
Genetic Promoter Regions
Epigenomics
Neoplasms
Proteins
Immunohistochemistry
Biopsy
Polymerase Chain Reaction
Genes

Keywords

  • Adenoma
  • biomarker
  • cell-free DNA
  • colorectal cancer
  • DNA methylation
  • liquid biopsy
  • plasma

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. / Barták, Barbara Kinga; Kalmár, Alexandra; Péterfia, Bálint; Patai, Árpád V.; Galamb, O.; Valcz, Gábor; Spisák, S.; Wichmann, Barnabás; Nagy, Zsófia Brigitta; Tóth, Kinga; Tulassay, Z.; Igaz, P.; Molnár, B.

In: Epigenetics, Vol. 12, No. 9, 02.09.2017, p. 751-763.

Research output: Contribution to journalArticle

Barták, Barbara Kinga ; Kalmár, Alexandra ; Péterfia, Bálint ; Patai, Árpád V. ; Galamb, O. ; Valcz, Gábor ; Spisák, S. ; Wichmann, Barnabás ; Nagy, Zsófia Brigitta ; Tóth, Kinga ; Tulassay, Z. ; Igaz, P. ; Molnár, B. / Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. In: Epigenetics. 2017 ; Vol. 12, No. 9. pp. 751-763.
@article{93f28a114c57494990818988211f2747,
title = "Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples",
abstract = "Aberrant methylation is one of the most frequent epigenetic alterations that can contribute to tumor formation. Cell-free DNA can originate from tumor tissue; therefore, the evaluation of methylation markers in cell-free DNA can be a promising method for cancer screening. Our aim was to develop a panel of biomarkers with altered methylation along the colorectal adenoma-carcinoma sequence in both colonic tissue and plasma. Methylation of selected CpG sites in healthy colonic (n = 15), adenoma (n = 15), and colorectal cancer (n = 15) tissues was analyzed by pyrosequencing. MethyLight PCR was applied to study the DNA methylation of SFRP1, SFRP2, SDC2, and PRIMA1 gene promoters in 121 plasma and 32 biopsy samples. The effect of altered promoter methylation on protein expression was examined by immunohistochemistry. Significantly higher (P < 0.05) DNA methylation levels were detected in the promoter regions of all 4 markers, both in CRC and adenoma tissues compared with healthy controls. Methylation of SFRP1, SFRP2, SDC2, and PRIMA1 promoter sequences was observed in 85.1{\%}, 72.3{\%}, 89.4{\%}, and 80.9{\%} of plasma samples from patients with CRC and 89.2{\%}, 83.8{\%}, 81.1{\%} and 70.3{\%} from adenoma patients, respectively. When applied as a panel, CRC patients could be distinguished from controls with 91.5{\%} sensitivity and 97.3{\%} specificity [area under the curve (AUC) = 0.978], while adenoma samples could be differentiated with 89.2{\%} sensitivity and 86.5{\%} specificity (AUC = 0.937). Immunohistochemical analysis indicated decreasing protein levels of all 4 markers along the colorectal adenoma-carcinoma sequence. Our findings suggest that this methylation biomarker panel allows non-invasive detection of colorectal adenoma and cancer from plasma samples.",
keywords = "Adenoma, biomarker, cell-free DNA, colorectal cancer, DNA methylation, liquid biopsy, plasma",
author = "Bart{\'a}k, {Barbara Kinga} and Alexandra Kalm{\'a}r and B{\'a}lint P{\'e}terfia and Patai, {{\'A}rp{\'a}d V.} and O. Galamb and G{\'a}bor Valcz and S. Spis{\'a}k and Barnab{\'a}s Wichmann and Nagy, {Zs{\'o}fia Brigitta} and Kinga T{\'o}th and Z. Tulassay and P. Igaz and B. Moln{\'a}r",
year = "2017",
month = "9",
day = "2",
doi = "10.1080/15592294.2017.1356957",
language = "English",
volume = "12",
pages = "751--763",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples

AU - Barták, Barbara Kinga

AU - Kalmár, Alexandra

AU - Péterfia, Bálint

AU - Patai, Árpád V.

AU - Galamb, O.

AU - Valcz, Gábor

AU - Spisák, S.

AU - Wichmann, Barnabás

AU - Nagy, Zsófia Brigitta

AU - Tóth, Kinga

AU - Tulassay, Z.

AU - Igaz, P.

AU - Molnár, B.

PY - 2017/9/2

Y1 - 2017/9/2

N2 - Aberrant methylation is one of the most frequent epigenetic alterations that can contribute to tumor formation. Cell-free DNA can originate from tumor tissue; therefore, the evaluation of methylation markers in cell-free DNA can be a promising method for cancer screening. Our aim was to develop a panel of biomarkers with altered methylation along the colorectal adenoma-carcinoma sequence in both colonic tissue and plasma. Methylation of selected CpG sites in healthy colonic (n = 15), adenoma (n = 15), and colorectal cancer (n = 15) tissues was analyzed by pyrosequencing. MethyLight PCR was applied to study the DNA methylation of SFRP1, SFRP2, SDC2, and PRIMA1 gene promoters in 121 plasma and 32 biopsy samples. The effect of altered promoter methylation on protein expression was examined by immunohistochemistry. Significantly higher (P < 0.05) DNA methylation levels were detected in the promoter regions of all 4 markers, both in CRC and adenoma tissues compared with healthy controls. Methylation of SFRP1, SFRP2, SDC2, and PRIMA1 promoter sequences was observed in 85.1%, 72.3%, 89.4%, and 80.9% of plasma samples from patients with CRC and 89.2%, 83.8%, 81.1% and 70.3% from adenoma patients, respectively. When applied as a panel, CRC patients could be distinguished from controls with 91.5% sensitivity and 97.3% specificity [area under the curve (AUC) = 0.978], while adenoma samples could be differentiated with 89.2% sensitivity and 86.5% specificity (AUC = 0.937). Immunohistochemical analysis indicated decreasing protein levels of all 4 markers along the colorectal adenoma-carcinoma sequence. Our findings suggest that this methylation biomarker panel allows non-invasive detection of colorectal adenoma and cancer from plasma samples.

AB - Aberrant methylation is one of the most frequent epigenetic alterations that can contribute to tumor formation. Cell-free DNA can originate from tumor tissue; therefore, the evaluation of methylation markers in cell-free DNA can be a promising method for cancer screening. Our aim was to develop a panel of biomarkers with altered methylation along the colorectal adenoma-carcinoma sequence in both colonic tissue and plasma. Methylation of selected CpG sites in healthy colonic (n = 15), adenoma (n = 15), and colorectal cancer (n = 15) tissues was analyzed by pyrosequencing. MethyLight PCR was applied to study the DNA methylation of SFRP1, SFRP2, SDC2, and PRIMA1 gene promoters in 121 plasma and 32 biopsy samples. The effect of altered promoter methylation on protein expression was examined by immunohistochemistry. Significantly higher (P < 0.05) DNA methylation levels were detected in the promoter regions of all 4 markers, both in CRC and adenoma tissues compared with healthy controls. Methylation of SFRP1, SFRP2, SDC2, and PRIMA1 promoter sequences was observed in 85.1%, 72.3%, 89.4%, and 80.9% of plasma samples from patients with CRC and 89.2%, 83.8%, 81.1% and 70.3% from adenoma patients, respectively. When applied as a panel, CRC patients could be distinguished from controls with 91.5% sensitivity and 97.3% specificity [area under the curve (AUC) = 0.978], while adenoma samples could be differentiated with 89.2% sensitivity and 86.5% specificity (AUC = 0.937). Immunohistochemical analysis indicated decreasing protein levels of all 4 markers along the colorectal adenoma-carcinoma sequence. Our findings suggest that this methylation biomarker panel allows non-invasive detection of colorectal adenoma and cancer from plasma samples.

KW - Adenoma

KW - biomarker

KW - cell-free DNA

KW - colorectal cancer

KW - DNA methylation

KW - liquid biopsy

KW - plasma

UR - http://www.scopus.com/inward/record.url?scp=85029896464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029896464&partnerID=8YFLogxK

U2 - 10.1080/15592294.2017.1356957

DO - 10.1080/15592294.2017.1356957

M3 - Article

C2 - 28753106

AN - SCOPUS:85029896464

VL - 12

SP - 751

EP - 763

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

IS - 9

ER -